Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

When demand from a large customer outstrips your production capacity, propose a strategic financing arrangement. Ask them to help fund your expansion in exchange for a guaranteed volume contract, such as by pre-paying for a large future order or co-investing in a specific equipment line.

Despite numerous announcements of new US pharmaceutical factories, tangible production capacity is not immediate. Building a highly automated facility, procuring machinery, and integrating it takes 18-24 months alone. A realistic timeline for significant output from these new investments is three to five years.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.

Rather than waiting for positive Phase 2 results, Transgene is using part of its €105M financing to prepare its manufacturing processes for a potential Phase 3 trial. This strategic foresight aims to prevent manufacturing delays and accelerate the timeline to market if the data is successful.

The primary driver for outsourcing in the pharmaceutical industry is no longer just a need for more manufacturing capacity. It has strategically shifted towards seeking specialized expertise and partnerships, particularly in complex areas like CMC (Chemistry, Manufacturing, and Controls) where the process defines the product.